In Second Term At Helm, Would Califf Steer US FDA On Supplement Market Regulation Changes?
CRN and NPA are receptive to former FDA Commissioner Robert Califf’s potential return to the post. NPA says his previous comments on FDA’s authority is a good sign he may help act on supplement industry issues stalled within the agency in recent years.
You may also be interested in...
Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.
UCLA professor Chris Tang says like most US businesses relying on supplies or production from outside the country, particularly from China, consumer health and beauty and personal care product companies should expect at least another year of supply disruption.
Acting commissioner's comment on supplement industry regulation was her most definitive statement about the agency’s work in consumer health sector at CHPA's regulatory conference. Pandemic, she says, heightened consumer interest in self-care along with demand for OTC drugs and supplements.